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Abstract The second cysteine-rich (Cys-2) domain of rat brain
PKC-Q regulatory region C1 (92^173) was expressed in
Escherichia coli cells and purified. NMR studies of Cys-2
protein identified the phorbol and other phospholipid binding
sites within this molecule (Xu, R.X., Pawelczyk, T., Xia, T-H.
and Brown, S.T. (1997) Biochemistry 37, 10709^10717). Here,
we tested the ability of this domain to bind other proteins. Using
an overlay assay we show that the Cys-2 domain binds other
proteins in Xenopus oocyte soluble fraction. Unlike the kinase
activity, binding of Cys-2 to other proteins was detected in the
absence of added phospholipids. Microinjection of Cys-2 protein
into Xenopus leavis oocytes inhibited insulin-induced but not
progesterone-induced maturation. the smallest dose that en-
hanced insulin-induced maturation was 0.45U10312 mol injected
Cys-2. These results demonstrate that the PKC-Q Cys-2 domain
beside being the binding site for phorbol ester/DAG and
phosphatidylserine binds also other proteins. The proteins that
interact with Cys-2 domain of PKC are essential for insulin-
induced maturation program in oocytes.
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1. Introduction
Protein kinase C (PKC) is a family of at least 11 serine/
threonine kinases that represent the key components of intra-
cellular signal transduction [1,2]. Based on their structure and
cofactor regulation the PKC isozymes have been classi¢ed
into three groups, i.e. conventional (K, LI, LII, Q), novel (N,
O, R, a, W) and atypical (j, V). Members of the PKC family are
a single polypeptide composed of an N-terminal regulatory
region and a C-terminal catalytic region. Multiple, function-
ally distinct segments are present within the regulatory and
catalytic segments. The regulatory region of conventional
PKCs which participate in autoinhibition and transient acti-
vation of the enzyme have a C1, C2 and V1 domain [3]. The
C1 domain contains a duplicated cys-rich motif (Cys-1, Cys-2)
responsive to DAG/phorbol ester [4,5]. The C2 domain binds
Ca2 and acidic lipids [6]. However, more detailed studies of
phorbol ester binding to individual segments of PKC-Q C1
region namely Cys-1 and Cys-2 revealed a complex mecha-
nism involving phospholipids, phorbol esters and divalent cat-
ions [7,8]. These studies established that a single cysteine-rich
domain (Cys-2) of PKC-Q contains regions necessary and suf-
¢cient for PS and calcium-dependent stereospeci¢c interac-
tions with phorbol esters [8,9]. Moreover, the Cys-2 domain
appears to be su⁄cient to confer translocation of a fusion
protein to lipid membrane in a phorbol ester and DAG-de-
pendent fashion [8].
Upon activation of several signalling events in the cell, the
PKC isozymes translocate to new cellular compartments [10^
12]. With the use of immuno£uorescence technic unique sub-
cellular localization for individual PKCs has been demon-
strated [13^15]. It has been postulated that in addition to
being e¡ector molecules, PKC substrates also bind to the
kinase directly. Recently, several proteins associating with
PKC have been discovered [16^18]. It was proposed that the
regulatory domains of the PKCs contain important determi-
nants of the PKC interactions with other proteins [19]. Such
assumption is supported by the observation that binding of
RACK1 to PKC-L takes place at the C2 region [15,16]. The
calcium-dependent and phospholipid-independent binding of
neuronal substrate GAP-43 to V0/C2 region of PKC-N was
also reported [20]. The ENH protein, which contains the cys-
rich domains (LIM domain) binds to the PKC-L1 and PKC-O
through the interaction with the V1 region [21]. It was dem-
onstrated that the PH domains of kinases Btk and Emt (mem-
bers of Tec family protein tyrosine kinases) interact with PKC
[22,23]. Recently, direct protein-protein interaction between
the C1 region of PKC and PH domain of kinase Btk have
been reported [24]. Moreover, interaction of these proteins
was shown to be dependent on phorbol ester and phosphatid-
ylinositol 4,5-bisphosphate binding. Our studies showed that
the Cys-2 domain of PKC-Q binds some proteins in phospho-
lipid-independent fashion, and the other proteins in phospha-
tidylserine-dependent manner (Pawelczyk, T., Kowara, R.,
Dettla¡, A. and Matecki, A., manuscript in preparation).
We assumed that the Cys-2 peptide when injected into the
cell should inhibit (by the competition) PKC-dependent sig-
nalling in this cell if these interactions are critical for that
process. In order to examine our hypothesis we injected puri-
¢ed recombinant PKC-Q Cys-2 protein into Xenopus leavis
oocytes. Presented data showed that injection of Cys-2 protein
into oocytes at micromolar concentration blocked insulin-in-
duced maturation.
2. Materials and methods
Insulin, 3-aminobenzoic acid ethyl ester methane sulfonate salt (Tri-
cane), glutathione-agarose, and glutathione were from Sigma-Aldrich
Sp. z o.o. (Poznan, Poland). Bovine plasminogen free thrombin was
from Calbiochem-Novabiochem (La Jolla, USA). Collagenase type I
was purchased from Boehringer (Mannheim, Germany).
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The Cys-2 domain (92^173) was cloned into pGEM-2TKG vector
and expressed in E. coli BL21(DE3) cells as a fusion protein as de-
scribed previously [9]. The GST Cys-2 protein was puri¢ed on gluta-
thione-agarose column, and the Cys-2 protein was cleaved from glu-
tathione S-transferase (GST) by thrombin digestion. Cleaved Cys-2
protein was ¢nally puri¢ed on Mono-S (HR 5/5) column as described
[9].
Protein was determined by the method of Bradford [25] using bo-
vine serum albumin as standard.
2.1. Preparation of tissue extracts
X. leavis oocytes (average diameter of 1.2 mm) were homogenized
in two volumes of 10 mM HEPES-NaOH, pH 7.2, 5 mM MgCl2,
25 mM KCl, 1 mM Pefabloc SC, 5 WM leupeptin, 1 WM aprotinin
using a power-driven pestle. The homogenate was centrifuged at
120 000Ug for 1 h. The resulting supernatant (in 1 ml portions) was
stored at 320‡C as the soluble fraction. The sediment from ultracen-
trifugation was suspended in 2 volumes of homogenization bu¡er
supplemented with 200 mM NaCl and homogenized in a glass homog-
enizer with a motor-driven Te£on pestle. The resulting homogenate
was supplemented with sodium chelate to a ¢nal concentration of
1.2%. After stirring for 60 min at 4‡C, insoluble material was removed
by centrifugation at 40 000Ug for 1 h. The supernatant was stored (in
1 ml portions) at 320‡C as the particulate fraction.
2.2. Antibodies
Polyclonal antibody to the PKC-Q Cys-2 protein was generated in
rabbits. Rabbits were subcutaneously injected in the back of the neck
with 400 Wg of puri¢ed antigen in Freund’s adjuvant followed by three
boosts with 200 Wg of antigen every 3 weeks. The antibody was pu-
ri¢ed by ammonium sulfate precipitation and by chromatography on
protein A-agarose column.
2.3. Immunoblots
The samples (100 Wg of protein) were separated on 10% SDS-PAGE
according to Laemmli [26] and then electrophoretically transferred to
nitrocellulose membrane. The membrane was blocked with 5% non-
fat milk powder in phosphate-bu¡ered saline (PBS) with 0.02% NaN3
and then washed with PBS.
2.4. Overlay assay
The overlay assay was used as described previously by Susan
Jaken’s group [15] with minor modi¢cations. The blocked membrane
strips were incubated for 1 h in TBS (50 mM Tris-HCl, pH 7.4,
0.5 M NaCl) containing 100 Wg/ml puri¢ed PKC-Q Cys-2 protein, 10
mg/ml bovine serum albumin, 1 mM Pefabloc SC, 5 WM leupeptin,
1 WM aprotinin, 1 mM EGTA, 1.1 mM CaCl2. After incubation with
Cys-2 protein, samples were washed with PBS containing required
cofactors and ¢xed with 0.5% formaldehyde in PBS for 20 min.
Next, the reactive aldehyde groups were blocked by incubation with
2% glycine in PBS for 20 min. The membrane strips were washed
three times in TBS and incubated with rabbit anti-rat PKC-Q Cys-2
polyclonal antibodies. Immunostaining was done using alkaline
phosphatase-conjugated goat anti-rabbit IgG, the chromogenic sub-
strate 5-bromo-4-chloro-3-indoyl phosphate and Nitro Blue Tetrazo-
lium.
2.5. Oocyte preparation
Oocytes were prepared following standard procedures [27]. Brie£y,
X. leavis (Blades Biological, England) were anesthetized by placing
individual frogs in 0.1% Tricane for 30^60 min. Ovaries were removed
from the frog, cut into small pieces and placed in Barth Medium (BM)
without Ca2 (110 mM NaCl, 2 mM KCl, 1 mM MgCl2, 2 mM
NaHCO3, 10 mM HEPES, pH 7.8). Oocytes were isolated by treating
these pieces with type I collagenase (2 mg/ml). After extensive wash-
ing, healthy stage VI oocytes (approx. 1.2 mm diameter) were selected
for assays. Either Cys-2 protein or bu¡er alone were injected (40 nl)
into oocytes. Oocytes were cultured at 18‡C in BM with 1 mM CaCl2.
Oocyte maturation was induced by the addition of 1 WM insulin [28]
or 1 Wg/ml progesterone [29]. Oocyte maturation was assessed at dif-
ferent times (in 1 h intervals) by the appearance of a white spot in the
animal pole due to germinal vesicle (nuclear) breakdown (GVBD). In
some cases, to con¢rm visual observations, nuclear breakdown was
con¢rmed by dissection of trichloroacetic acid (10%) ¢xed oocytes
[30].
3. Results
The process of oocyte maturation is initiated by the action
of agonist at the oocyte surface. This is followed by activation
of a cytoplasmic maturation-promoting factor which induces
the observed events associated with maturation [31]. Depend-
ing on maturation inducer, di¡erent signalling events occurred
in oocytes. The cAMP and Ca2-dependent signalling system
is the most extensively studied system in the oocytes [32].
Progesterone, which is the physiological inducer of oocyte
maturation triggers this signalling pathway. The key compo-
nents of the progesterone-induced signalling are protein kin-
ase A (PKA), the proto-oncogene product Mos and cyclin B
[32]. On the other hand it has been demonstrated that onco-
protein Ras and protein kinase C (PKC) are important com-
ponents of the insulin-induced maturation [33^36]. Peptides
derived from the fragments of proteins that bind to the
PKC-L (RACK1 and annexin I) a¡ected the PKC transloca-
tion and insulin-induced maturation upon injection into X.
leavis oocytes [15]. Our studies on Cys-2 domain (91^172) of
PKC-Q revealed that this domain beside binding DAG/phor-
bol esters and phospholipids binds also other proteins in rat
brain extracts (Pawelczyk, T., Kowara, R., Dettla¡, A. and
Matecki, A., manuscript in preparation). Using an overlay
assay system we were able to detect also in X. leavis oocyte
soluble fraction proteins that bind to the Cys-2 protein (Fig.
1). However, no binding proteins were detected in the partic-
ulate fraction of oocytes. In order to evaluate if the protein
interactions within Cys-2 domain of PKC are essential for
insulin-induced GVBD we injected the puri¢ed recombinant
Cys-2 protein into X. leavis oocytes. Microinjection of the
Cys-2 protein inhibited insulin-induced GVBD (Fig. 2). This
inhibition was dose dependent and after 23 h, only 30% of the
oocytes reached maturation when microinjected with
3.6U10312 mol of Cys-2 protein, as compared with maximal
maturation at 11 h in control injected (10 mM HEPES, pH
7.5) oocytes (Fig. 2). The smallest dose that enhanced insulin-
induced oocyte maturation was 0.45U10312 mol of Cys-2.
The average size of our oocytes was 1.2 mm. Thus, it can
be calculated that the average oocyte volume was 0.9 Wl.
One can calculate that the Cys-2 protein a¡ected the insu-
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Fig. 1. Binding of Cys-2 protein to proteins in Xenopus leavis oocyte
extract. The proteins (100 Wg) from oocyte soluble (strip A) and
particulate (strip B) fraction were separated by SDS-PAGE, trans-
ferred to nitrocellulose membrane and incubated with Cys-2 protein
in the presence of 0.1 mM CaCl2 as described in Section 2. Bound
Cys-2 protein was detected with puri¢ed anti-Cys-2 antibody. The
positions of molecular mass markers (in kDa) are indicated on the
left.
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lin-induced oocyte maturation at concentration as low as 0.5
WM. When the Cys-2 protein was injected to reach the con-
centration of 1 WM only 50% of the oocytes reached matura-
tion at 11 h, as compared with maximal maturation (100%)
observed at this time point in control injected oocytes (Fig. 2).
We did not detect any changes in progesterone-induced oocyte
maturation upon injection of Cys-2 protein (Fig. 3). In the
presence of 1 Wg/ml progesterone 100% oocytes reached ma-
turation within 7 h regardless Cys-2 injection. Under em-
ployed conditions Cys-2 in doses up to 9U10312 mol did
not enhance progesterone-induced maturation of oocytes.
These results demonstrate that the Cys-2 protein acts on spe-
ci¢c critical step(s) in the oocyte maturation program induced
by insulin but not by progesterone.
4. Discussion
A number of recent studies suggest that PKC isozymes act
on speci¢c substrates by means of binding to variety of an-
choring proteins as well as to other proteins that translocate
the enzyme to certain regions of the cell [16,17]. Most of the
identi¢ed to date proteins that bind PKC isozymes interact
with them within the regulatory region of the kinase. The
interaction within speci¢c domains is the means by which
each PKC isoform recognizes its speci¢c substrate or binding
protein. Such assumption is supported by several observa-
tions. Binding of RACK1 (receptor for activated C-kinase)
to PKC-L takes place at the C2 region [36]. The peptide
LC2-4 derived from the sequences of the interacting domains
inhibits the PKC binding to RACK in vitro and inhibits the
PKC-mediated function in vivo [15,37,38]. Introduction of
OV1-2 octapeptide derived from the RACK binding site of
PKC-O into rat islets abolished glucose-induced translocation
of PKC-O [39]. These peptides were used as novel PKC iso-
zyme-speci¢c inhibitors to determine the speci¢c function of
individual isozymes [38,39]. The calcium-dependent and phos-
pholipid-independent binding of neuronal substrate GAP-43
to PKC-N takes place within V0/C2 region [20]. The protein
ENH, which contains the cys-rich domains (LIM domains)
binds to the PKC-L1 and PKC-O through the interaction
with the V1 region of PKC. This protein does not bind to
PKC-K, N and j [21]. Our results for the ¢rst time demonstrate
that PKC-Q Cys-2 domain beside being the binding site for
phorbol ester/DAG and phosphatidylserine binds also other
proteins. The proteins that interact with Cys-2 domain are
crucial components of insulin-induced but not progesterone-
induced maturation signalling cascades in oocyte. We assume
that injected Cys-2 protein binds to proteins in oocyte and
inhibits by competition endogenous PKC. However, it should
be emphasized that competition of Cys-2 protein with endog-
enous PKC for its physiological activator, i.e. diacylglycerol
may also leads to inhibition of the processes dependent on
PKC action. Additional studies to determine if the localiza-
tion of the endogenous PKC is altered after Cys-2 injection
are required to fully address this problem. Future studies
should also lead to identi¢cation of the protein(s) that interact
with Cys-2 domain, as well as to identi¢cation of a segment
within Cys-2 domain that is responsible for the interaction
with other proteins.
References
[1] Nishizuka, Y. (1992) Science 258, 607^614.
[2] Dekker, L.V. and Parker, P.J. (1994) Trends Biochem. Sci. 19,
73^77.
[3] Newton, A.C. (1995) J. Biol. Chem. 270, 28495^28498.
[4] Ohno, Y., Fujii, T., Igarashi, K., Kuno, T., Tanaka, C., Kokka-
wa, U. and Nishizuka, Y. (1989) Proc. Natl. Acad. Sci. USA 86,
4868^4871.
[5] Quest, A.F.G., Bardes, E.S.G. and Bell, R.M. (1994) J. Biol.
Chem. 269, 2961^2970.
FEBS 19822 17-2-98
Fig. 3. Time course of progesterone-induced Xenopus leavis oocyte
maturation after injection of Cys-2 protein. Conditions were as de-
scribed in the legend to Fig. 2, except that oocytes were injected
with: 10 mM HEPES, pH 7.5 (vehicle, a), 0.9 pmol (S), 2.7 pmol
(E), 5.4 pmol (b), or 9 pmol (8) of Cys-2 protein. Progesterone (1
Wg/ml) was added 1 h later, and the development of GVBD in time
was monitored. Essentially identical results were obtained in three
other experiments.
Fig. 2. Time course of insulin-induced Xenopus leavis oocyte matu-
ration after injection of Cys-2 protein. Oocytes (in group of 20 for
each experimental condition) were injected (40 nl) with: 10 mM
HEPES, pH 7.5 (vehicle, a), 0.45 pmol (b), 0.9 pmol (O), 1.8 pmol
(8), or 3.6 pmol (E) of Cys-2 protein. Insulin (1 WM) was added
1 h later, and the development of GVBD in time was monitored.
Results are expressed as a percentage of oocytes reaching GVBD.
The concentrations shown were calculated based on an average
oocyte volume of 0.9 Wl. Presented results are representatives of
those obtained from four independent experiments.
T. Pawelczyk et al./FEBS Letters 423 (1998) 31^34 33
[6] Newton, A.C. (1995) Curr. Biol. 5, 973^976.
[7] Quest, A.F., Bardes, E.S.G. and Bell, R.M. (1994) J. Biol. Chem.
269, 2953^2960.
[8] Quest, A.F.G. and Bell, R.M. (1994) J. Biol. Chem. 269, 20000^
20012.
[9] Xu, R.X., Pawelczyk, T., Xia, T-H. and Brown, S.C. (1997)
Biochemistry 36, 10709^10717.
[10] Shoji, M., Girard, P.R., Mazzei, G.J., Vogler, W.R. and Kuo,
J.F. (1986) Biochem. Biophys. Res. Commun. 135, 1144^1149.
[11] Misra, U.K. and Sahyoun, N. (1987) Biochem. Biophys. Res.
Commun. 145, 760^768.
[12] Kiley, S.C. and Jaken, S. (1990) Mol. Endocrinol. 4, 59^68.
[13] Lehel, C., Olah, Z., Jakab, G. and Anderson, W.B. (1995) Proc.
Natl. Acad. Sci. USA 92, 1406^1410.
[14] Kiley, S.C. and Parker, P.J. (1995) Cell Sci. 108, 1003^1016.
[15] Ron, D. and Mochly-Rosen, D. (1994) J. Biol. Chem. 269,
21395^21398.
[16] Mochly-Rosen, D. (1995) Science 268, 247^251.
[17] Jaken, S. (1996) Curr. Opin. Cell. Biol. 8, 168^173.
[18] Faux, M.C. and Scott, J.D. (1996) Cell 85, 9^12.
[19] Liao, L., Hyatt, S.L., Chapline, C. and Jaken, S. (1994) Biochem-
istry 33, 1229^1233.
[20] Dekker, L.V. and Parker, P.J. (1997) J. Biol. Chem. 272, 12747^
12753.
[21] Kuroda, S., Tokunaga, C., Kiyohara, Y., Chiguchi, O., Konishi,
H., Mizuno, K., Gill, G.N. and Kikkawa, U. (1996) J. Biol.
Chem. 271, 31029^31032.
[22] Yao, L., Kawakami, Y. and Kawakami, T. (1994) Proc. Natl.
Acad. Sci. USA 19, 9175^9179.
[23] Kawakami, Y., Yao, L., Tashiro, M., Gibson, S., Mills, G.B. and
Kawakami, T. (1995) J. Immunol. 155, 3556^3562.
[24] Yao, L., Suzuki, H., Ozawa, K., Deng, J., Lehel, C., Fukamachi,
H., Anderson, W.B., Kawakami, Y. and Kawakami, T. (1997)
J. Biol. Chem. 272, 13033^13039.
[25] Bradford, M.M. (1976) Anal. Biochem. 72, 248^254.
[26] Leammli, U.K. (1970) Nature 227, 680^685.
[27] Colman, A. (1984) in: Transcription and Translation: A Practi-
cal Approach (Hames, B.D. and Higgins, S.J., Eds.), pp. 271^
300, URL Press, Washington, DC.
[28] Maller, J.L. and Koontz, H. (1981) Dev. Biol. 85, 309^316.
[29] Baulieu, E-E., Godeau, F., Schorderet, M. and Schorderet-Slat-
kine, S. (1978) Nature (Lond.) 275, 593^598.
[30] Billah, M.M., Eckel, S., Mullmann, T.J., Egan, R.W. and Siegel,
M.I. (1997) J. Biol. Chem. 264, 17069^17077.
[31] Smith, D. (1989) Development 107, 685^699.
[32] Matten, W.T. and Vande Woude, G.F. (1994) Dev. Biol. 5, 173^
181.
[33] Korn, L.J., Siebel, C.W., McCormic, F. and Roth, R.A. (1987)
Science 236, 840^843.
[34] Deshpande, A. and Kung, H.F. (1987) Mol. Cell. Biol. 7, 1285^
1288.
[35] Domingues, I., Diaz-Meco, M.T., Municio, M.M., Berra, E.,
Garcia de Herreros, A., Cornet, M.E., Santz, L. and Moscat,
J. (1992) Mol. Cell. Biol. 12, 3776^3783.
[36] Ron, D., Chen, C.H., Caldwell, J., Jamieson, L. and Mochly-
Rosen, D. (1994) Proc. Natl. Acad. Sci. USA 91, 839^843.
[37] Ron, D., Luo, J. and Mochly-Rosen, D. (1995) J. Biol. Chem.
270, 24180^24187.
[38] Yedovitzky, M., Mochly-Rosen, D., Johnson, J.A., Gray, O.M.,
Ron, D. and Nesher, R. (1997) J. Biol. Chem. 272, 1417^1420.
[39] Johnson, J.A., Gray, M.O., Chen, C.H. and Mochly-Rosen, D.
(1996) J. Biol. Chem. 271, 24962^24966.
FEBS 19822 17-2-98
T. Pawelczyk et al./FEBS Letters 423 (1998) 31^3434
